[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fW-3a5rbkMXczJ401XTWY1q4elfcBYC21-Xoaecr2Bl8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":49,"rows":56},"BioCryst Pharmaceuticals",[4],54,false,3,14,4393,2,0,[14,16,19,22,25,27,29,31],{"name":15,"count":9},"Hereditary Angioedema",{"name":17,"count":18},"Influenza",7,{"name":20,"count":21},"HAE",6,{"name":23,"count":24},"Paroxysmal Nocturnal Hemoglobinuria",4,{"name":26,"count":24},"Gout",{"name":28,"count":24},"Lymphoma",{"name":30,"count":11},"Seasonal Influenza",{"name":32,"count":11},"Cough",[34,39,44],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT05453968","Berotralstat Treatment in Children With Hereditary Angioedema","2024-09-11","Berotralstat",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06539507","A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725","2026-10","BCX17725",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT04933721","Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies","2031-08","berotralstat",[50,51,52,53,54,55],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[57,95,119,217,294,343,374,403,426,444,469,548,614,636,658,691,719,737,761,779,797,822,847,870,888,911,929,954,972,1009,1032,1055,1081,1099,1117,1135,1153,1171],{"intervention":38,"totalTrials":8,"cells":58},{"EARLY_PHASE1":59,"PHASE1":61,"PHASE2":63,"PHASE3":65,"PHASE4":83,"NA":85},{"trials":60,"activeCount":12},[],{"trials":62,"activeCount":12},[],{"trials":64,"activeCount":12},[],{"trials":66,"activeCount":11,"soonestReadout":37},[67,76],{"nctId":35,"briefTitle":36,"status":68,"phases":69,"primaryCompletion":37,"completion":70,"start":71,"enrollment":72,"conditions":73,"interventions":75},"ACTIVE_NOT_RECRUITING",[53],"2027-02","2022-10-25",29,[15,74],"Pediatric",[38],{"nctId":45,"briefTitle":46,"status":77,"phases":78,"primaryCompletion":47,"completion":47,"start":79,"enrollment":80,"conditions":81,"interventions":82},"ENROLLING_BY_INVITATION",[53],"2021-07-23",139,[15,20],[48],{"trials":84,"activeCount":12},[],{"trials":86,"activeCount":12},[87],{"nctId":88,"briefTitle":89,"status":90,"phases":91,"conditions":92,"interventions":94},"NCT04428632","Oral Berotralstat Expanded Access Program","APPROVED_FOR_MARKETING",[],[15,20,93],"Prophylaxis",[38],{"intervention":43,"totalTrials":96,"cells":97},1,{"EARLY_PHASE1":98,"PHASE1":100,"PHASE2":111,"PHASE3":113,"PHASE4":115,"NA":117},{"trials":99,"activeCount":12},[],{"trials":101,"activeCount":96,"soonestReadout":42},[102],{"nctId":40,"briefTitle":41,"status":103,"phases":104,"primaryCompletion":42,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":110},"RECRUITING",[51],"2026-12","2024-09-26",78,[109],"Netherton Syndrome",[43],{"trials":112,"activeCount":12},[],{"trials":114,"activeCount":12},[],{"trials":116,"activeCount":12},[],{"trials":118,"activeCount":12},[],{"intervention":120,"totalTrials":121,"cells":122},"BCX7353",8,{"EARLY_PHASE1":123,"PHASE1":125,"PHASE2":161,"PHASE3":182,"PHASE4":213,"NA":215},{"trials":124,"activeCount":12},[],{"trials":126,"activeCount":12},[127,141,151],{"nctId":128,"briefTitle":129,"status":130,"phases":131,"primaryCompletion":132,"completion":132,"start":133,"enrollment":6,"conditions":134,"interventions":135},"NCT03136237","A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions","COMPLETED",[51],"2017-08-15","2017-02-17",[15],[120,136,137,138,139,140],"Digoxin","BCX7353 + digoxin","Rosuvastatin","rosuvastatin + BCX7353","Cyclosporine + BCX7353",{"nctId":142,"briefTitle":143,"status":130,"phases":144,"primaryCompletion":145,"completion":146,"start":147,"enrollment":148,"conditions":149,"interventions":150},"NCT02448264","First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers",[51],"2015-11","2015-12","2015-05",122,[15],[120],{"nctId":152,"briefTitle":153,"status":130,"phases":154,"primaryCompletion":155,"completion":156,"start":157,"enrollment":158,"conditions":159,"interventions":160},"NCT03202784","A Relative Bioavailability Study of Two Formulations of BCX7353",[51],"2017-08-01","2017-09-30","2017-02-27",24,[15],[120],{"trials":162,"activeCount":12},[163,173],{"nctId":164,"briefTitle":165,"status":130,"phases":166,"primaryCompletion":167,"completion":167,"start":168,"enrollment":169,"conditions":170,"interventions":172},"NCT02870972","Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema",[52],"2017-08","2016-08",75,[171],"Hereditary Angioedema (HAE)",[120],{"nctId":174,"briefTitle":175,"status":130,"phases":176,"primaryCompletion":177,"completion":177,"start":178,"enrollment":179,"conditions":180,"interventions":181},"NCT03240133","Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema",[52],"2019-01-29","2017-07-31",58,[171],[120],{"trials":183,"activeCount":12},[184,193,203],{"nctId":185,"briefTitle":186,"status":130,"phases":187,"primaryCompletion":188,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":192},"NCT03472040","A Long Term Safety Study of BCX7353 in Hereditary Angioedema",[52,53],"2022-04-27","2018-02-16",387,[15,20,93],[120],{"nctId":194,"briefTitle":195,"status":130,"phases":196,"primaryCompletion":197,"completion":197,"start":198,"enrollment":199,"conditions":200,"interventions":202},"NCT03873116","Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan",[53],"2021-07-08","2018-12-27",19,[201],"Hereditary Angioedema, HAE",[120,120],{"nctId":204,"briefTitle":205,"status":130,"phases":206,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":212},"NCT03485911","Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE",[53],"2019-04-10","2022-04-06","2018-02-06",121,[15,20],[120],{"trials":214,"activeCount":12},[],{"trials":216,"activeCount":12},[],{"intervention":218,"totalTrials":21,"cells":219},"Peramivir",{"EARLY_PHASE1":220,"PHASE1":222,"PHASE2":224,"PHASE3":237,"PHASE4":290,"NA":292},{"trials":221,"activeCount":12},[],{"trials":223,"activeCount":12},[],{"trials":225,"activeCount":12},[226],{"nctId":227,"briefTitle":228,"status":130,"phases":229,"primaryCompletion":230,"completion":231,"start":232,"enrollment":233,"conditions":234,"interventions":236},"NCT00705406","A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza",[52],"2009-04","2009-10","2008-07",405,[235],"Acute, Uncomplicated Human Influenza",[218],{"trials":238,"activeCount":12},[239,253,263,270,281],{"nctId":240,"briefTitle":241,"status":130,"phases":242,"primaryCompletion":243,"completion":244,"start":231,"enrollment":245,"conditions":246,"interventions":252},"NCT00957996","Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza",[53],"2010-10","2011-08",234,[30,32,247,248,249,250,251],"Sore Throat","Nasal Congestion","Myalgia","Headache","Fatigue",[218,218],{"nctId":254,"briefTitle":255,"status":256,"phases":257,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":261,"interventions":262},"NCT00610935","Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza","TERMINATED",[53],"2008-02","2008-01",82,[17],[218],{"nctId":264,"briefTitle":265,"status":256,"phases":266,"primaryCompletion":267,"completion":267,"start":243,"enrollment":96,"conditions":268,"interventions":269},"NCT01224795","A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.",[53],"2010-11",[17],[218],{"nctId":271,"briefTitle":272,"status":130,"phases":273,"primaryCompletion":274,"completion":275,"start":276,"enrollment":277,"conditions":278,"interventions":279},"NCT02369159","Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza",[53],"2019-10-28","2020-05-14","2015-03-11",137,[17],[218,280],"Oseltamivir",{"nctId":282,"briefTitle":283,"status":130,"phases":284,"primaryCompletion":285,"completion":286,"start":146,"enrollment":287,"conditions":288,"interventions":289},"NCT02635724","Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza",[53],"2018-04","2018-09",74,[17],[218],{"trials":291,"activeCount":12},[],{"trials":293,"activeCount":12},[],{"intervention":295,"totalTrials":24,"cells":296},"BCX4161",{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":318,"PHASE3":328,"PHASE4":339,"NA":341},{"trials":298,"activeCount":12},[],{"trials":300,"activeCount":12},[301,310],{"nctId":302,"briefTitle":303,"status":130,"phases":304,"primaryCompletion":305,"completion":305,"start":306,"enrollment":307,"conditions":308,"interventions":309},"NCT02125162","A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161",[51],"2014-07","2014-04",28,[15],[295],{"nctId":311,"briefTitle":312,"status":130,"phases":313,"primaryCompletion":314,"completion":314,"start":315,"enrollment":18,"conditions":316,"interventions":317},"NCT02218294","Study to Determine How BCX4161 is Metabolized and Eliminated by the Body",[51],"2014-09","2014-08",[15],[295],{"trials":319,"activeCount":12},[320],{"nctId":321,"briefTitle":322,"status":130,"phases":323,"primaryCompletion":324,"completion":324,"start":325,"enrollment":158,"conditions":326,"interventions":327},"NCT01984788","Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE",[52],"2014-05","2013-11",[15],[295],{"trials":329,"activeCount":12},[330],{"nctId":331,"briefTitle":332,"status":130,"phases":333,"primaryCompletion":334,"completion":334,"start":335,"enrollment":336,"conditions":337,"interventions":338},"NCT02303626","12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks",[52,53],"2016-01","2014-12-17",110,[15,20],[295],{"trials":340,"activeCount":12},[],{"trials":342,"activeCount":12},[],{"intervention":344,"totalTrials":11,"cells":345},"avoralstat",{"EARLY_PHASE1":346,"PHASE1":348,"PHASE2":359,"PHASE3":361,"PHASE4":370,"NA":372},{"trials":347,"activeCount":12},[],{"trials":349,"activeCount":12},[350],{"nctId":351,"briefTitle":352,"status":256,"phases":353,"primaryCompletion":354,"completion":354,"start":355,"enrollment":8,"conditions":356,"interventions":358},"NCT07228559","A Study of Avoralstat In Participants With Diabetic Macular Edema",[51],"2026-04-17","2025-10-02",[357],"Diabetic Macular Edema (DME)",[344],{"trials":360,"activeCount":12},[],{"trials":362,"activeCount":12},[363],{"nctId":364,"briefTitle":365,"status":256,"phases":366,"primaryCompletion":367,"completion":367,"start":146,"enrollment":21,"conditions":368,"interventions":369},"NCT02670720","Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema",[53],"2016-02",[15,20],[344],{"trials":371,"activeCount":12},[],{"trials":373,"activeCount":12},[],{"intervention":280,"totalTrials":11,"cells":375},{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":393,"PHASE4":399,"NA":401},{"trials":377,"activeCount":12},[],{"trials":379,"activeCount":12},[],{"trials":381,"activeCount":12},[382],{"nctId":383,"briefTitle":384,"status":130,"phases":385,"primaryCompletion":386,"completion":387,"start":388,"enrollment":277,"conditions":389,"interventions":390},"NCT00453999","Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza",[52],"2008-09","2009-08","2007-07",[17],[391,392,280],"Peramivir 200 mg","Peramivir 400 mg",{"trials":394,"activeCount":12},[395],{"nctId":271,"briefTitle":272,"status":130,"phases":396,"primaryCompletion":274,"completion":275,"start":276,"enrollment":277,"conditions":397,"interventions":398},[53],[17],[218,280],{"trials":400,"activeCount":12},[],{"trials":402,"activeCount":12},[],{"intervention":404,"totalTrials":96,"cells":405},"Peramivir 150mg",{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":410,"PHASE3":412,"PHASE4":422,"NA":424},{"trials":407,"activeCount":12},[],{"trials":409,"activeCount":12},[],{"trials":411,"activeCount":12},[],{"trials":413,"activeCount":12},[414],{"nctId":415,"briefTitle":416,"status":417,"phases":418,"enrollment":12,"conditions":419,"interventions":420},"NCT00486980","Intramuscular Peramivir for the Treatment of Uncomplicated Influenza","WITHDRAWN",[53],[17],[404,421],"Peramivir 300mg",{"trials":423,"activeCount":12},[],{"trials":425,"activeCount":12},[],{"intervention":421,"totalTrials":96,"cells":427},{"EARLY_PHASE1":428,"PHASE1":430,"PHASE2":432,"PHASE3":434,"PHASE4":440,"NA":442},{"trials":429,"activeCount":12},[],{"trials":431,"activeCount":12},[],{"trials":433,"activeCount":12},[],{"trials":435,"activeCount":12},[436],{"nctId":415,"briefTitle":416,"status":417,"phases":437,"enrollment":12,"conditions":438,"interventions":439},[53],[17],[404,421],{"trials":441,"activeCount":12},[],{"trials":443,"activeCount":12},[],{"intervention":445,"totalTrials":96,"cells":446},"Peramivir+SOC",{"EARLY_PHASE1":447,"PHASE1":449,"PHASE2":451,"PHASE3":453,"PHASE4":465,"NA":467},{"trials":448,"activeCount":12},[],{"trials":450,"activeCount":12},[],{"trials":452,"activeCount":12},[],{"trials":454,"activeCount":12},[455],{"nctId":456,"briefTitle":457,"status":256,"phases":458,"primaryCompletion":459,"completion":460,"start":461,"enrollment":233,"conditions":462,"interventions":464},"NCT00958776","A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza",[53],"2012-11","2013-10","2009-11",[32,247,248,250,463,30],"Fever",[445],{"trials":466,"activeCount":12},[],{"trials":468,"activeCount":12},[],{"intervention":470,"totalTrials":18,"cells":471},"forodesine hydrochloride",{"EARLY_PHASE1":472,"PHASE1":474,"PHASE2":494,"PHASE3":542,"PHASE4":544,"NA":546},{"trials":473,"activeCount":12},[],{"trials":475,"activeCount":12},[476,485],{"nctId":477,"briefTitle":478,"status":130,"phases":479,"primaryCompletion":480,"completion":481,"start":482,"conditions":483,"interventions":484},"NCT00098332","Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma",[51],"2010-12","2011-07","2004-11",[28],[470],{"nctId":486,"briefTitle":487,"status":130,"phases":488,"primaryCompletion":489,"start":490,"conditions":491,"interventions":493},"NCT00073944","BCX-1777 in Treating Patients With Refractory Cancer",[51],"2005-01","2003-04",[492],"Cancer",[470],{"trials":495,"activeCount":12},[496,507,516,523,534],{"nctId":497,"briefTitle":498,"status":130,"phases":499,"primaryCompletion":500,"completion":501,"start":502,"enrollment":503,"conditions":504,"interventions":506},"NCT00095381","Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia",[52],"2007-03","2007-12","2004-03",20,[505],"Leukemia, T-Cell",[470],{"nctId":508,"briefTitle":509,"status":130,"phases":510,"primaryCompletion":511,"completion":511,"start":512,"enrollment":121,"conditions":513,"interventions":515},"NCT00289549","Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)",[52],"2009-01","2005-06",[514],"Leukemia, Lymphocytic, Chronic",[470],{"nctId":517,"briefTitle":518,"status":130,"phases":519,"primaryCompletion":489,"completion":259,"start":520,"conditions":521,"interventions":522},"NCT00061880","BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma",[51,52],"2003-02",[28],[470],{"nctId":524,"briefTitle":525,"status":256,"phases":526,"primaryCompletion":500,"completion":500,"start":527,"enrollment":528,"conditions":529,"interventions":531},"NCT00419081","Study of Forodesine Hydrochloride in Patients With Relapsed\u002FRefractory Precursor T-Lymphoblastic Leukemia\u002FLymphoma Who Have Failed Two or More Prior Treatment Regimens",[52],"2006-07",100,[530,28],"Leukemia",[532,533],"Forodesine Hydrochloride Sterile Solution, 5 mg\u002FmL","Forodesine Hydrochloride",{"nctId":535,"briefTitle":536,"status":130,"phases":537,"primaryCompletion":501,"completion":501,"start":538,"enrollment":503,"conditions":539,"interventions":541},"NCT00289562","Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia",[51,52],"2004-09",[540],"B-cell Acute Lymphoblastic Leukemia",[470],{"trials":543,"activeCount":12},[],{"trials":545,"activeCount":12},[],{"trials":547,"activeCount":12},[],{"intervention":549,"totalTrials":550,"cells":551},"BCX9930",5,{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":608,"PHASE4":610,"NA":612},{"trials":553,"activeCount":12},[],{"trials":555,"activeCount":12},[],{"trials":557,"activeCount":12},[558,566,577,589,598],{"nctId":559,"briefTitle":560,"status":256,"phases":561,"primaryCompletion":562,"completion":562,"start":563,"enrollment":307,"conditions":564,"interventions":565},"NCT05741346","Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria",[52],"2025-01-31","2023-01-18",[23],[549],{"nctId":567,"briefTitle":568,"status":256,"phases":569,"primaryCompletion":570,"completion":570,"start":571,"enrollment":11,"conditions":572,"interventions":576},"NCT05162066","Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)",[52],"2022-09-23","2022-02-18",[573,574,575],"Complement 3 Glomerulopathy","Immunoglobulin A Nephropathy","Membranous Nephropathy",[549],{"nctId":578,"briefTitle":579,"status":256,"phases":580,"primaryCompletion":581,"completion":581,"start":582,"enrollment":583,"conditions":584,"interventions":586},"NCT05116774","BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy",[52],"2023-09-14","2021-12-06",12,[585],"Paroxysmal Nocturnal Hemoglobinuria (PNH)",[587,588,549],"Eculizumab","Ravulizumab",{"nctId":590,"briefTitle":591,"status":256,"phases":592,"primaryCompletion":593,"completion":593,"start":594,"enrollment":199,"conditions":595,"interventions":597},"NCT04702568","A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)",[52],"2023-10-04","2020-12-18",[23,596],"PNH",[549,587,588],{"nctId":599,"briefTitle":600,"status":130,"phases":601,"primaryCompletion":602,"completion":603,"start":604,"enrollment":605,"conditions":606,"interventions":607},"NCT04330534","First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH",[51,52],"2020-11-11","2021-01-25","2020-03-03",168,[23],[549],{"trials":609,"activeCount":12},[],{"trials":611,"activeCount":12},[],{"trials":613,"activeCount":12},[],{"intervention":587,"totalTrials":11,"cells":615},{"EARLY_PHASE1":616,"PHASE1":618,"PHASE2":620,"PHASE3":630,"PHASE4":632,"NA":634},{"trials":617,"activeCount":12},[],{"trials":619,"activeCount":12},[],{"trials":621,"activeCount":12},[622,626],{"nctId":578,"briefTitle":579,"status":256,"phases":623,"primaryCompletion":581,"completion":581,"start":582,"enrollment":583,"conditions":624,"interventions":625},[52],[585],[587,588,549],{"nctId":590,"briefTitle":591,"status":256,"phases":627,"primaryCompletion":593,"completion":593,"start":594,"enrollment":199,"conditions":628,"interventions":629},[52],[23,596],[549,587,588],{"trials":631,"activeCount":12},[],{"trials":633,"activeCount":12},[],{"trials":635,"activeCount":12},[],{"intervention":588,"totalTrials":11,"cells":637},{"EARLY_PHASE1":638,"PHASE1":640,"PHASE2":642,"PHASE3":652,"PHASE4":654,"NA":656},{"trials":639,"activeCount":12},[],{"trials":641,"activeCount":12},[],{"trials":643,"activeCount":12},[644,648],{"nctId":578,"briefTitle":579,"status":256,"phases":645,"primaryCompletion":581,"completion":581,"start":582,"enrollment":583,"conditions":646,"interventions":647},[52],[585],[587,588,549],{"nctId":590,"briefTitle":591,"status":256,"phases":649,"primaryCompletion":593,"completion":593,"start":594,"enrollment":199,"conditions":650,"interventions":651},[52],[23,596],[549,587,588],{"trials":653,"activeCount":12},[],{"trials":655,"activeCount":12},[],{"trials":657,"activeCount":12},[],{"intervention":659,"totalTrials":11,"cells":660},"BCX4208",{"EARLY_PHASE1":661,"PHASE1":663,"PHASE2":665,"PHASE3":685,"PHASE4":687,"NA":689},{"trials":662,"activeCount":12},[],{"trials":664,"activeCount":12},[],{"trials":666,"activeCount":12},[667,676],{"nctId":668,"briefTitle":669,"status":130,"phases":670,"primaryCompletion":267,"completion":267,"start":671,"enrollment":672,"conditions":673,"interventions":674},"NCT01129648","Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w\u002FGout",[52],"2010-05",87,[26],[675,675,675,659,675,675,675,659,675,675,675,659,675,675,675,659],"Allopurinol",{"nctId":677,"briefTitle":678,"status":130,"phases":679,"primaryCompletion":680,"completion":680,"start":681,"enrollment":682,"conditions":683,"interventions":684},"NCT00985127","Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout",[52],"2010-09","2009-09",99,[26],[659],{"trials":686,"activeCount":12},[],{"trials":688,"activeCount":12},[],{"trials":690,"activeCount":12},[],{"intervention":692,"totalTrials":96,"cells":693},"Ulodesine (BCX4208) 5 mg",{"EARLY_PHASE1":694,"PHASE1":696,"PHASE2":698,"PHASE3":713,"PHASE4":715,"NA":717},{"trials":695,"activeCount":12},[],{"trials":697,"activeCount":12},[],{"trials":699,"activeCount":12},[700],{"nctId":701,"briefTitle":702,"status":130,"phases":703,"primaryCompletion":704,"completion":704,"start":705,"enrollment":503,"conditions":706,"interventions":711},"NCT01407874","A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency",[52],"2012-07","2011-09",[26,707,708,709,710],"Hyperuricemia","Arthritis","Joint Disease","Renal Insufficiency",[692,712],"Ulodesine (BCX4208) 10 mg",{"trials":714,"activeCount":12},[],{"trials":716,"activeCount":12},[],{"trials":718,"activeCount":12},[],{"intervention":712,"totalTrials":96,"cells":720},{"EARLY_PHASE1":721,"PHASE1":723,"PHASE2":725,"PHASE3":731,"PHASE4":733,"NA":735},{"trials":722,"activeCount":12},[],{"trials":724,"activeCount":12},[],{"trials":726,"activeCount":12},[727],{"nctId":701,"briefTitle":702,"status":130,"phases":728,"primaryCompletion":704,"completion":704,"start":705,"enrollment":503,"conditions":729,"interventions":730},[52],[26,707,708,709,710],[692,712],{"trials":732,"activeCount":12},[],{"trials":734,"activeCount":12},[],{"trials":736,"activeCount":12},[],{"intervention":738,"totalTrials":96,"cells":739},"BCX-1777",{"EARLY_PHASE1":740,"PHASE1":742,"PHASE2":744,"PHASE3":755,"PHASE4":757,"NA":759},{"trials":741,"activeCount":12},[],{"trials":743,"activeCount":12},[],{"trials":745,"activeCount":12},[746],{"nctId":747,"briefTitle":748,"status":130,"phases":749,"completion":502,"start":750,"enrollment":751,"conditions":752,"interventions":754},"NCT00035022","Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas",[51,52],"2001-08",71,[753,28],"Leukemia, Lymphocytic",[738],{"trials":756,"activeCount":12},[],{"trials":758,"activeCount":12},[],{"trials":760,"activeCount":12},[],{"intervention":391,"totalTrials":96,"cells":762},{"EARLY_PHASE1":763,"PHASE1":765,"PHASE2":767,"PHASE3":773,"PHASE4":775,"NA":777},{"trials":764,"activeCount":12},[],{"trials":766,"activeCount":12},[],{"trials":768,"activeCount":12},[769],{"nctId":383,"briefTitle":384,"status":130,"phases":770,"primaryCompletion":386,"completion":387,"start":388,"enrollment":277,"conditions":771,"interventions":772},[52],[17],[391,392,280],{"trials":774,"activeCount":12},[],{"trials":776,"activeCount":12},[],{"trials":778,"activeCount":12},[],{"intervention":392,"totalTrials":96,"cells":780},{"EARLY_PHASE1":781,"PHASE1":783,"PHASE2":785,"PHASE3":791,"PHASE4":793,"NA":795},{"trials":782,"activeCount":12},[],{"trials":784,"activeCount":12},[],{"trials":786,"activeCount":12},[787],{"nctId":383,"briefTitle":384,"status":130,"phases":788,"primaryCompletion":386,"completion":387,"start":388,"enrollment":277,"conditions":789,"interventions":790},[52],[17],[391,392,280],{"trials":792,"activeCount":12},[],{"trials":794,"activeCount":12},[],{"trials":796,"activeCount":12},[],{"intervention":798,"totalTrials":96,"cells":799},"Forodesine 200 mg",{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":804,"PHASE3":816,"PHASE4":818,"NA":820},{"trials":801,"activeCount":12},[],{"trials":803,"activeCount":12},[],{"trials":805,"activeCount":12},[806],{"nctId":807,"briefTitle":808,"status":130,"phases":809,"primaryCompletion":810,"completion":811,"start":388,"enrollment":812,"conditions":813,"interventions":815},"NCT00501735","Forodesine in the Treatment of Cutaneous T-Cell Lymphoma",[52],"2010-07","2011-12",144,[814],"Cutaneous T-cell Lymphoma (CTCL),",[798],{"trials":817,"activeCount":12},[],{"trials":819,"activeCount":12},[],{"trials":821,"activeCount":12},[],{"intervention":823,"totalTrials":96,"cells":824},"forodesine HCl",{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":829,"PHASE3":841,"PHASE4":843,"NA":845},{"trials":826,"activeCount":12},[],{"trials":828,"activeCount":12},[],{"trials":830,"activeCount":12},[831],{"nctId":832,"briefTitle":833,"status":130,"phases":834,"primaryCompletion":267,"completion":835,"start":836,"enrollment":837,"conditions":838,"interventions":840},"NCT00640523","Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)",[52],"2011-11","2008-03",23,[839],"Chronic Lymphocytic Leukemia (CLL)",[823],{"trials":842,"activeCount":12},[],{"trials":844,"activeCount":12},[],{"trials":846,"activeCount":12},[],{"intervention":848,"totalTrials":96,"cells":849},"BCX9930 monotherapy",{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":854,"PHASE3":864,"PHASE4":866,"NA":868},{"trials":851,"activeCount":12},[],{"trials":853,"activeCount":12},[],{"trials":855,"activeCount":12},[856],{"nctId":857,"briefTitle":858,"status":256,"phases":859,"primaryCompletion":860,"completion":860,"start":861,"enrollment":583,"conditions":862,"interventions":863},"NCT05116787","BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy",[52],"2023-09-18","2021-10-26",[585],[848],{"trials":865,"activeCount":12},[],{"trials":867,"activeCount":12},[],{"trials":869,"activeCount":12},[],{"intervention":675,"totalTrials":96,"cells":871},{"EARLY_PHASE1":872,"PHASE1":874,"PHASE2":876,"PHASE3":882,"PHASE4":884,"NA":886},{"trials":873,"activeCount":12},[],{"trials":875,"activeCount":12},[],{"trials":877,"activeCount":12},[878],{"nctId":668,"briefTitle":669,"status":130,"phases":879,"primaryCompletion":267,"completion":267,"start":671,"enrollment":672,"conditions":880,"interventions":881},[52],[26],[675,675,675,659,675,675,675,659,675,675,675,659,675,675,675,659],{"trials":883,"activeCount":12},[],{"trials":885,"activeCount":12},[],{"trials":887,"activeCount":12},[],{"intervention":889,"totalTrials":96,"cells":890},"ulodesine",{"EARLY_PHASE1":891,"PHASE1":893,"PHASE2":895,"PHASE3":905,"PHASE4":907,"NA":909},{"trials":892,"activeCount":12},[],{"trials":894,"activeCount":12},[],{"trials":896,"activeCount":12},[897],{"nctId":898,"briefTitle":899,"status":130,"phases":900,"primaryCompletion":704,"completion":901,"start":480,"enrollment":902,"conditions":903,"interventions":904},"NCT01265264","Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol",[52],"2013-02",279,[26,707,708,709],[889],{"trials":906,"activeCount":12},[],{"trials":908,"activeCount":12},[],{"trials":910,"activeCount":12},[],{"intervention":532,"totalTrials":96,"cells":912},{"EARLY_PHASE1":913,"PHASE1":915,"PHASE2":917,"PHASE3":923,"PHASE4":925,"NA":927},{"trials":914,"activeCount":12},[],{"trials":916,"activeCount":12},[],{"trials":918,"activeCount":12},[919],{"nctId":524,"briefTitle":525,"status":256,"phases":920,"primaryCompletion":500,"completion":500,"start":527,"enrollment":528,"conditions":921,"interventions":922},[52],[530,28],[532,533],{"trials":924,"activeCount":12},[],{"trials":926,"activeCount":12},[],{"trials":928,"activeCount":12},[],{"intervention":930,"totalTrials":96,"cells":931},"Peramivir 150 mg",{"EARLY_PHASE1":932,"PHASE1":934,"PHASE2":936,"PHASE3":948,"PHASE4":950,"NA":952},{"trials":933,"activeCount":12},[],{"trials":935,"activeCount":12},[],{"trials":937,"activeCount":12},[938],{"nctId":939,"briefTitle":940,"status":130,"phases":941,"primaryCompletion":942,"completion":942,"start":943,"enrollment":944,"conditions":945,"interventions":946},"NCT00419263","Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.",[52],"2007-09","2007-01",344,[17],[930,947],"Peramivir 300 mg",{"trials":949,"activeCount":12},[],{"trials":951,"activeCount":12},[],{"trials":953,"activeCount":12},[],{"intervention":947,"totalTrials":96,"cells":955},{"EARLY_PHASE1":956,"PHASE1":958,"PHASE2":960,"PHASE3":966,"PHASE4":968,"NA":970},{"trials":957,"activeCount":12},[],{"trials":959,"activeCount":12},[],{"trials":961,"activeCount":12},[962],{"nctId":939,"briefTitle":940,"status":130,"phases":963,"primaryCompletion":942,"completion":942,"start":943,"enrollment":944,"conditions":964,"interventions":965},[52],[17],[930,947],{"trials":967,"activeCount":12},[],{"trials":969,"activeCount":12},[],{"trials":971,"activeCount":12},[],{"intervention":973,"totalTrials":11,"cells":974},"Galidesivir",{"EARLY_PHASE1":975,"PHASE1":977,"PHASE2":1001,"PHASE3":1003,"PHASE4":1005,"NA":1007},{"trials":976,"activeCount":12},[],{"trials":978,"activeCount":12},[979,990],{"nctId":980,"briefTitle":981,"status":256,"phases":982,"primaryCompletion":983,"completion":984,"start":985,"enrollment":158,"conditions":986,"interventions":989},"NCT03891420","A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19",[51],"2021-01-31","2021-04-30","2020-04-09",[987,988],"COVID-19","Yellow Fever",[973],{"nctId":991,"briefTitle":992,"status":130,"phases":993,"primaryCompletion":994,"completion":994,"start":995,"enrollment":996,"conditions":997,"interventions":999},"NCT03800173","A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430",[51],"2019-04-30","2018-12-10",32,[998],"Marburg Virus Disease",[1000],"galidesivir",{"trials":1002,"activeCount":12},[],{"trials":1004,"activeCount":12},[],{"trials":1006,"activeCount":12},[],{"trials":1008,"activeCount":12},[],{"intervention":1010,"totalTrials":96,"cells":1011},"BCX10013",{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1024,"PHASE3":1026,"PHASE4":1028,"NA":1030},{"trials":1013,"activeCount":12},[],{"trials":1015,"activeCount":12},[1016],{"nctId":1017,"briefTitle":1018,"status":130,"phases":1019,"primaryCompletion":1020,"completion":1020,"start":1021,"enrollment":121,"conditions":1022,"interventions":1023},"NCT06100900","Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)",[51],"2024-12-11","2023-10-24",[23],[1010],{"trials":1025,"activeCount":12},[],{"trials":1027,"activeCount":12},[],{"trials":1029,"activeCount":12},[],{"trials":1031,"activeCount":12},[],{"intervention":1033,"totalTrials":96,"cells":1034},"BCX7353 and probes",{"EARLY_PHASE1":1035,"PHASE1":1037,"PHASE2":1047,"PHASE3":1049,"PHASE4":1051,"NA":1053},{"trials":1036,"activeCount":12},[],{"trials":1038,"activeCount":12},[1039],{"nctId":1040,"briefTitle":1041,"status":130,"phases":1042,"primaryCompletion":1043,"completion":1043,"start":1044,"enrollment":503,"conditions":1045,"interventions":1046},"NCT02819102","An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates",[51],"2016-06","2016-03",[15],[1033],{"trials":1048,"activeCount":12},[],{"trials":1050,"activeCount":12},[],{"trials":1052,"activeCount":12},[],{"trials":1054,"activeCount":12},[],{"intervention":1056,"totalTrials":96,"cells":1057},"BCX4430",{"EARLY_PHASE1":1058,"PHASE1":1060,"PHASE2":1073,"PHASE3":1075,"PHASE4":1077,"NA":1079},{"trials":1059,"activeCount":12},[],{"trials":1061,"activeCount":12},[1062],{"nctId":1063,"briefTitle":1064,"status":130,"phases":1065,"primaryCompletion":1044,"completion":1066,"start":1067,"enrollment":1068,"conditions":1069,"interventions":1072},"NCT02319772","A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430",[51],"2016-04","2014-12",94,[1070,1071],"Filovirus Infections","Ebola Virus Infection",[1056],{"trials":1074,"activeCount":12},[],{"trials":1076,"activeCount":12},[],{"trials":1078,"activeCount":12},[],{"trials":1080,"activeCount":12},[],{"intervention":136,"totalTrials":96,"cells":1082},{"EARLY_PHASE1":1083,"PHASE1":1085,"PHASE2":1091,"PHASE3":1093,"PHASE4":1095,"NA":1097},{"trials":1084,"activeCount":12},[],{"trials":1086,"activeCount":12},[1087],{"nctId":128,"briefTitle":129,"status":130,"phases":1088,"primaryCompletion":132,"completion":132,"start":133,"enrollment":6,"conditions":1089,"interventions":1090},[51],[15],[120,136,137,138,139,140],{"trials":1092,"activeCount":12},[],{"trials":1094,"activeCount":12},[],{"trials":1096,"activeCount":12},[],{"trials":1098,"activeCount":12},[],{"intervention":137,"totalTrials":96,"cells":1100},{"EARLY_PHASE1":1101,"PHASE1":1103,"PHASE2":1109,"PHASE3":1111,"PHASE4":1113,"NA":1115},{"trials":1102,"activeCount":12},[],{"trials":1104,"activeCount":12},[1105],{"nctId":128,"briefTitle":129,"status":130,"phases":1106,"primaryCompletion":132,"completion":132,"start":133,"enrollment":6,"conditions":1107,"interventions":1108},[51],[15],[120,136,137,138,139,140],{"trials":1110,"activeCount":12},[],{"trials":1112,"activeCount":12},[],{"trials":1114,"activeCount":12},[],{"trials":1116,"activeCount":12},[],{"intervention":138,"totalTrials":96,"cells":1118},{"EARLY_PHASE1":1119,"PHASE1":1121,"PHASE2":1127,"PHASE3":1129,"PHASE4":1131,"NA":1133},{"trials":1120,"activeCount":12},[],{"trials":1122,"activeCount":12},[1123],{"nctId":128,"briefTitle":129,"status":130,"phases":1124,"primaryCompletion":132,"completion":132,"start":133,"enrollment":6,"conditions":1125,"interventions":1126},[51],[15],[120,136,137,138,139,140],{"trials":1128,"activeCount":12},[],{"trials":1130,"activeCount":12},[],{"trials":1132,"activeCount":12},[],{"trials":1134,"activeCount":12},[],{"intervention":139,"totalTrials":96,"cells":1136},{"EARLY_PHASE1":1137,"PHASE1":1139,"PHASE2":1145,"PHASE3":1147,"PHASE4":1149,"NA":1151},{"trials":1138,"activeCount":12},[],{"trials":1140,"activeCount":12},[1141],{"nctId":128,"briefTitle":129,"status":130,"phases":1142,"primaryCompletion":132,"completion":132,"start":133,"enrollment":6,"conditions":1143,"interventions":1144},[51],[15],[120,136,137,138,139,140],{"trials":1146,"activeCount":12},[],{"trials":1148,"activeCount":12},[],{"trials":1150,"activeCount":12},[],{"trials":1152,"activeCount":12},[],{"intervention":140,"totalTrials":96,"cells":1154},{"EARLY_PHASE1":1155,"PHASE1":1157,"PHASE2":1163,"PHASE3":1165,"PHASE4":1167,"NA":1169},{"trials":1156,"activeCount":12},[],{"trials":1158,"activeCount":12},[1159],{"nctId":128,"briefTitle":129,"status":130,"phases":1160,"primaryCompletion":132,"completion":132,"start":133,"enrollment":6,"conditions":1161,"interventions":1162},[51],[15],[120,136,137,138,139,140],{"trials":1164,"activeCount":12},[],{"trials":1166,"activeCount":12},[],{"trials":1168,"activeCount":12},[],{"trials":1170,"activeCount":12},[],{"intervention":1172,"totalTrials":96,"cells":1173},"Peldesine",{"EARLY_PHASE1":1174,"PHASE1":1176,"PHASE2":1185,"PHASE3":1187,"PHASE4":1189,"NA":1191},{"trials":1175,"activeCount":12},[],{"trials":1177,"activeCount":12},[1178],{"nctId":1179,"briefTitle":1180,"status":130,"phases":1181,"conditions":1182,"interventions":1184},"NCT00002237","A Study of Peldesine (BCX-34) in HIV-Infected Patients",[51],[1183],"HIV Infections",[1172],{"trials":1186,"activeCount":12},[],{"trials":1188,"activeCount":12},[],{"trials":1190,"activeCount":12},[],{"trials":1192,"activeCount":12},[]]